490 BioTech

[On Demand]
490 BioTech develops next-generation toxicity assay systems to support economic, high throughout, 3D and co-culture compatible screening with only a single preparation step. These assays use light in the visible spectrum, just like existing bioluminescent/fluorescent assays, to continuously indicate real-time metabolic activity/viability dynamics for up to 7 days from undisturbed samples, but do not require any external activation to function. This reduces both measurement error and assay cost by eliminating steps and perturbation from existing workflows, while maintaining your same equipment and testing conditions. This drop-in replacement capability, combined with improved functionality, enables exciting new capabilities and accelerates existing research by producing more data, reducing costs, and enabling continuous automated tracking without requiring perturbation at any point throughout the data collection process.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Ready-To-Use Toxicity Assay Mix
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Scientific Officer
490 BioTech Inc.